Design Principles For Antibody Drug Conjugates Adc

Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.

Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

An Anti‐CD147 Antibody−Drug Conjugate Mehozumab‐DM1 is Efficacious Against Hepatocellular Carcinoma in Cynomolgus Monkey

A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant

Engineered Ultrasmall Nanoparticle Drug-Immune Conjugates with "Hit and Run" Tumor Delivery to Eradicate Gastr

TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid

Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity wi

Shifting the paradigm in personalized cancer care through next‐generation therapeutics and computational pathology

Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potenti

Therapeutic Targeting of Osteosarcoma and Lung Metastases in Preclinical Models Using a CD24 Antibody‐Drug Conjugate

Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and

Azobenzene-based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder C

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Ins

A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly.

Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.

Ethynylphosphonamidates for the Rapid and Cysteine‐Selective Generation of Efficacious Antibody–Drug Conjugates

Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma

Analyzing protein conjugation reactions for antibody‐drug conjugate synthesis using polarized excitation emission matrix

The Methylene Alkoxy Carbamate Self-Immolative Unit: Utilization for the Targeted Delivery of Alcohol-Containing Payload

N‐Hydroxysuccinimide‐Modified Ethynylphosphonamidates Enable the Synthesis of Configurationally Defined Protein Conjugat

Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation

Advancements in Targeted Therapies for Colorectal Cancer: Innovative Drug Formulation and Delivery Strategies

Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches

Optimal treatment of early stage HER2‐positive breast cancer

Assembly of pH-Responsive Antibody-Drug-Inspired Conjugates.

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy

A Novel Concept for Cleavable Linkers Applicable to Conjugation Chemistry – Design, Synthesis and Characterization

Quantitative collision‐induced unfolding differentiates model antibody–drug conjugates

Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold

Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls

Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneo

Antibody Drug Conjugate Formation Using 2-14C-Iminothiolane: A Radiochemical Analysis of Sequential Lysine Conjugation,

Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl au

Targeted therapies in bladder cancer: signaling pathways, applications, and challenges

In Silico Structural Analysis of Human β‐Glucuronidase for Antibody–Drug Conjugates Optimization

Intact quantitation of cysteine-conjugated antibody-drug conjugates using native mass spectrometry.

The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refr

Site-Specific Conjugation to Cys-Engineered THIOMAB™ Antibodies.

Peptide-Drug Conjugates: A New Hope for Cancer.

Utilizing Solid-Phase to Enable High-Throughput, Site-Specific Conjugation and Dual-Labeled Antibody and Fab Conjugates.

Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.

Site-Specific Bioconjugation Using SMARTag® Technology: A Practical and Effective Chemoenzymatic Approach to Generate An

Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyt

Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecu

Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.

Research progress of CD22-targeting antibody-drug conjugates

Research progress of antibody-drug conjugate targeting B cell maturation antigen in treatment of relapsed/refractory mul

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogon

Antibody–Drug Conjugates: Bridging Science and Therapeutics

TCR-like antibody duocarmycin conjugates promote cytotoxicity of tumor cells expressing low peptide/HLA targets

Antibody-Drug Conjugates For the Treatment of Hematological Malignancy

Chemical strategies for linker design in antibody-drug conjugates : Enhancing stability and efficacy

Antibody Therapeutics in Oncology

[Oncology. Antibody-drug conjugates : a challenging innovation].

A new perspective in the research of antibody drug conjugate

Click chemistry in drug development recent trends and application

Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer

Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

Antibody–drug conjugates in B-cell lymphomas: current evidence and future directions

Antibody-Drug Conjugates, the Combination of Large and Small Therapeutic Molecules

HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric

Factors Influencing the Adoption of Antibody-Drug Conjugates in Oncology: A Statistical Study

Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer

A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity prediction

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastat

Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies

Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical rele

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential.

Future potential targets of antibody-drug conjugates in breast cancer.

Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to

Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resol

Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.

A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.

Bispecific antibody drug conjugates: Making 1+1>2.

Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy.

Antibody-drug conjugate [ADC] treatment of leukaemia.

Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery.

Drug deconjugation-assisted peptide mapping by LC-MS/MS to identify conjugation sites and quantify site occupancy for an

Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy.

Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using

Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed/Refractory Lymphomas.

Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies

Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.

Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.

Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-

Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.

Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconj

Bottom-Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in A

CMC Regulatory Considerations for Antibody-Drug Conjugates.

TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens th

In vivo safety testing of Antibody Drug Conjugates.

Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index.

Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through

Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.

A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Base

Characterization of Positional Isomers of Interchain Cysteine Linked Antibody-Drug Conjugates by High-Resolution Mass Sp

Digestion-Free Middle-Down Mass Spectrometry Method for Absolute Quantification of Conjugated Payload from Antibody-Drug

Cysteine-Based Coupling: Challenges and Solutions.

Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after

A Universal Affinity Capture LC-MS Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates i

Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying

A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineere

Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an

A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates wit

Site-specific conjugation of native antibodies using engineered microbial transglutaminases.

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.

Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-

Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Mo

Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody Drug Conjugate.

Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-

Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.

Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for

Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Rec

Synthesis and Evaluation of Three Azide-Modified Disaccharide Oxazolines as Enzyme Substrates for Single-Step Fc Glycan-

One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antib

PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates.

Generation and Characterization of Iduronidase-Cleavable ADCs.

Evaluation of Cellular Targeting by Fab' vs Full-Length Antibodies in Antibody-Nanoparticle Conjugates (ANCs) Using

Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy

Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies

One-Pot Assembly of Dual-Site-Specific Antibody-Drug Conjugates via Glycan Remodeling and Affinity-Directed Traceless Co

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates.

Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and D

Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity.

Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in A

Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cl

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Ma

Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parame

Mechanistic Characterization of the Potency of THIOMAB Antibody-Drug Conjugates Targeting Staphylococcus aureus and ETbR

One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.

Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release.

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Abstract LB522: Fibroblast activation protein triggers the release of drug payload from non-internalizing small molecule

Abstract 1541: NextGen conditionally active biologic (CAB) anti-Nectin-4-ADC with improved stability and safety

Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options

Abstract 1876: NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of potent pa

Abstract 1542: Generation of an antibody-drug conjugate-optimized TLR 7/8 agonist payload

Abstract 1530: Gastric cancerantibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours

Abstract 2634: AMB302/GR1017, an antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor shows therapeutic potency

Abstract 2640: An innovative site-specific dual-payload antibody drug conjugate (dpADC) combining a novel Topo1 inhibito

Abstract 1879: A novel dual CAB nectin-4 x CD3 bispecific antibody targeting solid tumors

Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate s

- **DOI:** 10.1158/1538-7445.am2023-2012 - **Authors:** Ludovic Juen, A. Collier, A. Tolcher, Myriam M. Ouberai - **Year

Abstract 2013: Oxidized anthracycline payloads induce anti-tumor immunogenic cell-death and show linker-dependent tolera

Abstract 2648: In vivo efficacy and preclinical safety profile of NN3201, an anti-cKIT antibody-drug conjugate, for trea

Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-

Abstract 3253: CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale fo

Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tum

Abstract 2944: Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage/DC activation, antigen-presentation and anti-t

Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodi

Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy

Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treat

Abstract 438: Antibody drug conjugate using a novel anti-CDCP1 antibody with low hematopoietic stem-cell binding and rap

Abstract 4891: Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient pa

Abstract 456: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Abstract 4890: A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activit

Abstract 2977: A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor ef

Abstract 584: Doppel, an exosome mediated biomarker specific to tumor endothelial cells

Abstract 6300: Therapeutic potential of EO-3021/SYSA1801, a Claudin18.2 antibody-drug conjugate, for the treatment of CL

Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors

Abstract 6297: Rationale for the development of a differentiated Trop2 ADC

Abstract 596: Development and assessment of a novel tumor microenvironment activable linker (TMALIN) ADC platform for so

Abstract 6304: Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment

Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small mo

Abstract 595: Targeting metabolic vulnerability in brain-metastatic HER2+ breast cancer

Abstract 6308: Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist ant

Abstract 825: Targeted nanospheres for the treatment of cancer

Abstract 6296: Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronide-protected pyrroloben

Abstract 6325: A novel EGFR x MUC1 bispecific antibody-drug conjugate, BSA01, targets MUC1 transmembrane cleavage produc

Abstract LB209: An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells

Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficac

Abstract LB213: Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate

Abstract 6318: Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treat

Abstract 1885: Developing a biparatopic anti-ROR1 antibody drug conjugate BR111 for hematological and solid tumor treatm

Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose e

Abstract LB215: A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor e

Abstract 1858: Discovery of AT86474, a highly efficacious anti-ROR1 ADC utilizing a proprietary payload

Abstract 1882: DXC024, a novel anti-TROP2/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of hi

Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activit

Abstract 1869: The AI-powered KisoSeek™ platform identifies functional anti-TROP2 heavy-chain antibodies with potent ant

Abstract 1909: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced effi

Abstract 1812: Development of novel topoisomerase 1 inhibitor PBX-7 payload-based ADC including tandem cleavable linker

Abstract 1902: ADRX-0706 Nectin-4 antibody-drug conjugate PK/PD characterization elucidates its widened therapeutic wind

Abstract 1904: Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targetin

Abstract 1871: Discovery and characterization of NXV01c, an EGFR × cMET bispecific nanobody drug conjugate with potent a

Abstract 1896: Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical

Abstract 1872: A next generation treatment for Nectin-4 positive cancers - Preclinical characterization of LY4052031, an

Abstract 1893: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in vario

Abstract 2377: HER2-ADC efficacy is rooted in its induction of immunogenic cell death with FcGR activation and a systemi

Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expr

Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker f

Abstract 1919: Activity and affinity tuning next-generation immunotoxins for targeted therapy

Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity

Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has

Abstract 2360: ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models

Abstract 2614: GlycoConnect™ ADC toolbox expansion with high DAR technology

Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoi

Abstract 2056: Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targe

Abstract 2620: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent p

Abstract 2601: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolat

Abstract 2616: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical eff

Abstract 2617: BCG022, a novel HER3 × MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor

Abstract 2615: Preclinical development of a next generation antibody drug conjugate (ADC) targeting cMET for treatment o

Abstract 3135: BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecifi

Abstract 2621: Preclinical Efficacy of DM002, a bispecific HER3 × MUC1 antibody-drug conjugate with a novel DNA topoisom

Abstract 2591: Nonclinical ocular toxicity of a maytansinoid payload-antibody drug conjugate: Ocular tissue distribution

Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugat

Abstract 3131: Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastr

Abstract 3123: Preclinical characterization of AMB302/GQ1011, a first-in-class FGFR3 antibody-drug conjugate (ADC) with

Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor

Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL

Abstract 3133: A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity i

Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

Abstract 3149: Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and

Abstract 3136: Towards development of a novel biparatopic trop2-ADC

- **DOI:** 10.1158/1538-7445.am2024-3370 - **Authors:** L. Piggott, E. Imedio, Francesco Staehli - **Year:** 2024 - **Jo

Abstract 3124: MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity an

Abstract 3125: TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatm

Abstract 3212: Development of a Trop2/CD3 bispecific antibody with modulated Trop2 binding affinity as a novel immunothe

Abstract 4702: MediLink’s TMALIN ADC linker technology: Tumor microenvironment specific extracellular and intracellular

Abstract 4077: T cell targeting with PD-1-selective immune cell engagers based on GlycoConnect™ (GC™-ICEs) show excellen

Abstract 5820: An antibody drug conjugate platform based on novel camptothecin payloads with branch hydrophilic linkers

Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers

Abstract 479: Enhanced payload delivery for acute myeloid leukemia treatment through CD37-targeting DNA nanobots

Abstract 3210: Raptamer-drug conjugates as molecularly targeted cancer therapeutics

Abstract 3108: Antibody labeling reagents to rapidly screen for the binding and internalization of therapeutic antibodie

Abstract 4700: Induced phenotype targeted ADC by using caspase enzymatic cleavable peptide linker to overcome tumor hete

Abstract 5908: Angiosarcoma growth inhibition by targeting Doppel, a specific endothelial marker, with an antibody drug

Abstract 5896: Platform approach to develop antibodies specifically recognizing cancer-associated glycoforms

A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linker

Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer

Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes

Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates

Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index.

Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer

Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer

Biological therapy in elderly patients with acute myeloid leukemia

Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder canc

What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for onco

Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinicalimplications.

An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates

Future directions for antibody-drug conjugates in urothelial cancer.

CD33-D2 isoform characterization for advancement of its therapeutic potential.

Targeting CD123 in BPDCN: an emerging field

The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma

Advances in click chemistry for drug discovery and development

Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor act

Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

Investigating protein–excipient interactions of a multivalent VHH therapeutic protein using NMR spectroscopy

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2

Improved translation of stability for conjugated antibodies using an in vitro whole blood assay

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins.

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute my

Impact of linker-drug on ion exchange chromatography separation of antibody-drug conjugates

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in pro

Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen

A glyco-engineering approach for site-specific conjugation to Fab glycans.

Targeting cancer with antibody-drug conjugates: Promises and challenges.

Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineeri

3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development

Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in

The physiological limits of bispecific monoclonal antibody tissue targeting specificity.

CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies

Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers

Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug

Antibody-Drug Conjugates in breast cancer.

Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspectiv

Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells fo

New and emerging pharmacotherapies for management of multiple myeloma.

Tumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours

Novel fluorogenic indicators of antibody and biologic trafficking and lysosomal catabolism 2670

Simple and Rapid LC-MS/MS Methods for Quantifying Catabolites of Antibody-Drug Conjugates with SMCC Linker.

Radioimmunotherapy combined with antibody-drug conjugate-induced radiosensitization leads to long-term remission in myco

Targeting Universal CAR T cells via antibody-drug conjugates adaptors 4830

Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lympho

A disruptive clickable antibody design for the generation of antibody-drug conjugates.

- **DOI:** 10.1093/neuonc/noz175.177 - **Authors:** C. Achenbach, V. Blot, W. Weiss, M. Weller - **Year:** 2019 - **Jour

P06.02.B DECODING THE DIVERSE SURFACEOME LANDSCAPE IN MALIGNANT BRAIN TUMORS IDENTIFIES TARGET CANDIDATES FOR PERSONALIZ

P-1165. Development of Novel CD4+ Cell Targeting Antibody-Drug Conjugates for HIV Treatment

ADCNet: a unified framework for predicting the activity of antibody-drug conjugates

The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts

Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tum

Antibody-drug conjugates in breast cancer: the chemotherapy of the future?

Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications

The target invites a foe: antibody-drug conjugates in gynecologic oncology.

The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.

Antibody-drug conjugates in lung cancer: current landscape and future perspectives.

Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights fro

The initial management of multiple myeloma in the era of novel agents: 2021 and beyond

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myelom

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy

HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade

Cancer therapy with antibodies.

Tissue penetration to optimize PSMA ADCs

Unlocking the potential of antibody-drug conjugates for cancer therapy.

The clinical development of antibody–drug conjugates — lessons from leukaemia

CHAPTER 5. Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)

CHAPTER 20. Protein Toxins as Antibody–Drug Conjugate (ADC) Payloads

CHAPTER 2. Design Factors Important for Antibody–Drug Conjugate (ADC) Payloads

A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine amin

New linker structures applied in glycosite-specific antibody drug conjugates

Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody

CHAPTER 18. Tubulysins as Antibody–Drug Conjugate (ADC) Payloads

An MMAE-loaded PDL1 active targeting nanomedicine for the precision treatment of colon cancer.

Targeted delivery of alcohol-containing payloads with antibody-drug conjugates.

Harnessing acylhydrazone-oxime exchange reaction to achieve diverse synthesis of glycosite-specific antibody-drug conjug

Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

The medicinal chemistry evolution of antibody-drug conjugates.

Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins

Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)

Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target

Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs.

Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development.

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

Metabolism of bioconjugate therapeutics: why, when, and how?

Beyond cytotoxic potency: disposition features required to design ADC payload.

Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

Antibody-drug conjugates in breast cancer: From therapeutic and immune activation mechanisms to resistance prevention

Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer

Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lym

Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials

Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer

Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes

Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cel

Biotechnology at the Frontline of Cancer Treatment and Therapeutic Innovation

Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targetin

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

An array of 60,000 antibodies for proteome-scale antibody generation and target discovery

Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by Hi

Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues

842 A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functional

1184 SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression an

620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the ant

Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates

Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing

854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4,

The clinical landscape of antibody-drug conjugates in endometrial cancer

1188 Antibody substrate oligonucleotide conjugates (ASOCs): a new class of immunotherapeutic agents to inhibit metastasi

618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications

Predictive Platforms of Bond Cleavage and Drug Release Kinetics for Macromolecule-Drug Conjugates.

Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangio

A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzum

Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed An

Where does ISAC (immune-stimulating antibody conjugates) go from here?

Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.

The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.

Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Model

Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.

A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refra

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizum

Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.

Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination w

Targeting a Radiosensitizing Antibody–Drug Conjugate to a Radiation-Inducible Antigen

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cy

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Antibody-Drug Conjugates: Advancing from magic bullet to biological missile.

Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinic

Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conju

The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors

MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinas

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Brea

Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinica

Preclinical Characterization of an Antibody–Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Popu

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive B

Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodia

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When

Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-

Calicheamicin Antibody-Drug Conjugates with Improved Properties.

Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Po

Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Anti

Development of Novel Antibody–Camptothecin Conjugates

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-exp

PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and

ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable T

Targeted Delivery of TLR7 Agonists to the Tumor Microenvironment Enhances Tumor Immunity via Activation of Tumor-Residen

Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid

Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.

High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linke

Modulating Thiol p Ka Promotes Disulfide Formation at Physiological pH: An Elegant Strategy To Design Disulfide Cross-Li

Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers.

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates.

Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs.

Identification of a Novel Linker Enabling the Bioconjugation of a Cyclic Dinucleotide for the STING Antibody-Drug Conjug

Internalization of Influenza Virus and Cell Surface Proteins Monitored by Site-Specific Conjugation of Protease-Sensitiv

Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation t

Immolation of p-Aminobenzyl Ether Linker and Payload Potency and Stability Determine the Cell-Killing Activity of Antibo

Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates

Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells.

Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.

Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Im

Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing.

Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity.

Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody-Drug Conjugates.

Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attac

Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insight

Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC).

Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents.

Site-Specific Stability Evaluation of Antibody-Drug Conjugate in Serum Using a Validated Liquid Chromatography-Mass Spec

Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates

Evaluation of Double Self-Immolative Linker-Based Antibody-Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potentia

Recent Advances in Peptide Linkers of Antibody-Drug Conjugates.

Chemical Modification of Linkers Provides Stable Linker-Payloads for the Generation of Antibody-Drug Conjugates.

Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conju

Recent Advances in Peptide Linkers for Antibody-Drug Conjugates.

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Small Molecule-Drug Conjugates: An Emerging Drug Design Strategy for Targeted Therapeutics.

Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs).

Site-Selective Anti-PD-L1 Antibody-MMAE Conjugate for Enhanced NSCLC Therapy.

Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prosta

DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality.

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.

Detailed Structural Elucidation of Antibody-Drug Conjugate Biotransformation Species Using High Resolution Multiple Reac

Distinctive Low-Resolution Structural Features of Dimers of Antibody Drug Conjugates and Parent Antibody determined by S

Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers

Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.

AbClick Pro H: Scavenger-Free, Traceless Lys248 Conjugation Via O-Acyl Hydroxamate Chemistry for Homogeneous Antibody-Dr

Antibody-Drug Conjugates (ADCs) with Indolinobenzodiazepine Dimer (IGN) Payloads: DNA-Binding Mechanism of IGN Catabolit

Biological Evaluation of Cleavable Linkers in Exatecan-Based Antibody–Drug Conjugates: A Comparative Study of DXd and Ex

Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering.

Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers

Study on the Heterogeneity of T-DM1 and the Analysis of the Unconjugated Linker Structure under a Stable Conjugation Pro

High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibod

Evaluation of Antibody–Drug Conjugate Performances Using a Novel HPLC–DAD Method for Tumor-Specific Detection of DM4 and

Comparative Enzymatic and Stability Assays Reveal GPLG as an Effective Cathepsin B Cleavable Linker for Tumor-Targeting

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conju

Single Mutation on Trastuzumab Modulates the Stability of Antibody–Drug Conjugates Built Using Acetal-Based Linkers and

Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery

Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.

Synthesis and Biological Evaluation of Shishijimicin A-Type Linker-Drugs and Antibody-Drug Conjugates.

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Second Generation Tiancimycin-Based Antibody-Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifi

PSMA-Targeting Chimeras for Cell-Type-Specific Degradation of Surface Immune Checkpoint Protein PD-L1

Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy

Antibody-Drug Conjugates in Head and Neck Cancer

Evolving Therapeutic Paradigms in Bladder Cancer: the Impact of Immunotherapy and Antibody-Drug Conjugates

Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates

Development of Diazaborines as ROS Sensitive Linkers for the Construction of Stimuli-Responsive Antibody Drug Conjugates

Integrating Hematopoietic Stem Cell Transplantation (HSCT) and Targeted Antibody-Drug Conjugates (ADCs) in Leukemia Trea

Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate D

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Update on Emerging Therapies for Advanced Colorectal Cancer.

Antibody-Drug Conjugates: Patient and Treatment Selection.

Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New Challenges.

Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in

Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of a

A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectab

A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tum

A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophage

Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II

Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-hu

Development of novel MUC1-C targeting antibody-drug conjugate for pancreatic cancer treatment.

TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination wi

An engineered Trop2/CD3 bispecific antibody for treatment of gastric, pancreatic, and colorectal cancers.

Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I

A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.

JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early

RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A r

Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated p

Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.

A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.

An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacok

Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug De

Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metas

A retrospective cohort study to monitor real-world safety in patients with locally advanced or metastatic urothelial car

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug

First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients

Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.

CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-Ge

First-in-human study of JSKN016, a bispecific anti-TROP2/HER3 antibody drug conjugate (ADC): Antitumor activity in patie

An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).

Preclinical evaluation of the efficacy of anti-PVR antibody-drug conjugates combined with anti-PD-1 therapy for bladder

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combinatio

A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in

Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phas

The anti-STEAP1/PSMA ADC, DXC008: Assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties.

The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass

Ocular toxicity and tolerability of BCMA directed antibody drug conjugate (ADC) therapy in relapsed multiple myeloma (MM

NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or m

Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer.

Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacit

Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key P

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice.

Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.

SAT-304 Targeted Inhibition of Prostate Cancer Cells upon Acrolein-enabled Bioorthogonal Activation of Prodrugs

A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic c

A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander E

Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case St

Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.

ARB1002, a potential first-in-class CDH17-specific ADC, for treatment of pancreatic and other gastrointestinal cancers.

PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions

Validation of ADC Platform for Protein Concentration and the Drug-Antibody Ratio (DAR) using Variable Pathlength Technol

Exo-Linker: Positional Reconfiguration Driving Significant Advances in ADC Stability and Efficacy

Abstract 5481: A 3D bioprinted vascularized human tumor-on-a-Chip model for simultaneous evaluation of immunotherapeutic

Abstract 5452: Novel tryptophan-based antibody-drug conjugate (ADC) targeting EGFR-positive lung cancer demonstrates rob

Abstract 5459: Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical char

Abstract 5476: In vitro real-time evaluation of bystander effects of antibody-drug conjugates

Abstract 5675: ThiOBI® platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation

Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for th

Abstract 5731: BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antit

Abstract 5486: Bioluminescent assays for antibody-drug conjugate development: internalization and Fc-mediated functions

Abstract 5482: In vitro assays for prediction of ADC hematological toxicities: contribution of antibody, linker, and pay

Abstract 578: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of pro

Abstract 6072: Engineering and preclinical development of an anti-TROP2/PD-L1 bispecific antibody drug conjugate (ADC) f

Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use

Abstract 5734: Advancing ADC discovery with a highly versatile linker-camptothecin library

Abstract 5730: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolong

Abstract 5733: Design and synthesis of the novel camptothecin analog MF-6 for application into site-specific antibody-dr

Abstract 6743: Patient-derived organoids: an in vitro platform for evaluating ADC efficacy, potency, and specificity

Abstract 7336: B7-H7 is a novel ADC target for solid tumors and shows potent activity with multiple payload-linker techn

Abstract 6748: Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab a

Abstract 6081: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor acti

Abstract 6742: High-affinity human IgG1 antibody against GUCY2C for ADC development: Identification, characterization, a

Abstract 6735: E-cM-Topi, a potent EGFR-cMET bispecific antibody drug conjugate, with superior anti-tumor effect in non-

Abstract LB004: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MM

Abstract 7463: A linker platform for antibody drug conjugates (ADCs): expanding the therapeutic window

Abstract 6851: An integrated preclinical platform for antibody-drug conjugate development

Abstract 6755: Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and no

Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-exp

Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activit

- **DOI:** 10.1158/1538-7445.am2025-833 - **Authors:** M. Wu, Yao-Tsung Tsai, Chee Voon Yap - **Year:** 2025 - **Journal

Abstract A024: Insights across indications from the Pediatric Bespoke Therapeutic Development Workshop initiative

Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian canc

- **DOI:** 10.1158/1538-7445.am2025-lb135 - **Authors:** Yi Yang, Kaiqing Zhang, Kunying Hao, Chengzhang Shang - **Year:

Abstract 6832: SYS6041, a next-generation Folate Receptor α-targeted antibody-drug conjugates for the treatment of FRα-e

Abstract 3000: Impact of trastuzumab coating when prototyping immunoliposomes in breast cancer models: The more the merr

Abstract A071: Inverse Biomarker Exploring Technology (IBMET) Mathematical Identification of Cancer-Specific Epitopes an

Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkp

Abstract 237: Preclinical evaluation of anti-HER2 Antibody Targeted Amanitin Conjugates (ATACs) on HER2low breast cancer

Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose dise

Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavil

Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast ca

Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-exp

Abstract P6-17-39: BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of H

Abstract P3-08-52: Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer

Abstract C049: Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of

- **DOI:** 10.1158/1557-3125.advbc17-a36 - **Authors:** Jeffrey H. Wu, L. Muldoon, E. Neuwelt - **Year:** 2018 - **Journ

Abstract P1-18-36: The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth fac

Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA mon

Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Pha

Abstract SP113: The making of an ADC

Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study o

Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab rav

Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced

Abstract P4-08-18: Engineered Toxin Bodies Specific for TROP2 Positive Cancers

Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment

Abstract P1-07-27: Triple-negative breast cancer with bone marrow involvement and response after use of antibody-drug co

Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade ser

Abstract P4-12-17: Pre-clinical data and phase I design for PQ-203: a novel peptide-drug conjugate (PDC) targeting the S

Abstract P6-10-18: Developing novel lysyl oxidase (LOX) inhibitors to overcome chemotherapy resistance in triple negativ

- **DOI:** 10.1158/1557-3265.sabcs24-p4-04-39 - **Authors:** E. Giontella, E. Fiorio - **Year:** 2025 - **Journal:** Cli

Abstract P2-08-27: ICARUS-BREAST02: Safety, Tolerability, & Anti-tumor Activity of patritumab deruxtecan (HER3-DXd)

Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor f

Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.

Abstract NT-090: PRECLINICAL ACTIVITY AND SAFETY OF STRO-002, A NOVEL ADC TARGETING FOLATE RECEPTOR ALPHA FOR OVARIAN AN

Abstract P5-05-30: Unlocking the Therapeutic Potential of T DXd Enhertu Mechanisms of Action in HER2 Low Cancers and Imm

Abstract 538: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload

Abstract PO-006: ABBV-319: A CD19–targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell

Abstract P5-03-09: Evaluating Post-T-DXd Treatment Strategies in HER2-positive Metastatic Breast Cancer

Abstract A009: Development of monoclonal antibodies targeting truncated O-glycans expressed specifically by cancer cells

Abstract P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, com

Abstract IA23: Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1

Abstract PS8-07: Efficacy and Safety of GQ1005, a Promising HER2-ADC, in Patients with Metastatic HER2-Positive Breast C

Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

Emerging Role of Antibody Drug Conjugates (ADCs) in Therapeutics: An Appraisal

Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers

Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

[Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study

Drugs in development for small cell lung cancer

Bi-specific immunotherapy for gastrointestinal malignancies

Sacituzumab govitecan in triple-negative breast cancer

Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.

Antibody-Drug Conjugates as Novel and Potent Cancer Therapeutics

ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies.

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreat

Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy.

Comprehensive Overview on Antibody Drug Conjugates- A Promising Approach in Cancer Therapy

Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.

Antibody Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers.

Characterising novel Antibody-Drug Conjugate targets for ovarian cancer: Implications for patient stratification and pre

Antibody-Drug Nanoparticles for Combination Treatment of Breast Cancer Cells

Antibody drug conjugates: Progress, pitfalls, and promises

Belantamab Mafodotin: Advancing Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Bioorthogonal Tetrazine Carbamate Cleavage by Highly Reactive Trans-Cyclooctene.

Modern developments in germline pharmacogenomics for oncology prescribing

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Ta

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept As a Targ

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy

Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations.

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a

Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibo

No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapse

Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial T

ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplant

Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (RO

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens th

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Ca

A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129)

Debio 1562M, a Next Generation Antibody Drug Conjugate (ADC) Targeting CD37 for AML and MDS Treatment

Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Pa

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leuke

SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with R

Single Cell Multi-Omic Correlation of Single Nucleotide Variants, Copy Number Variation and Surface Epitopes for Clonal

Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma,

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Pr

Development of an Antibody-Drug Conjugate Targeting CADM1 in Adult T-Cell Leukemia/Lymphoma

CLEC2A Is a Novel AML-Restricted Immunotherapeutic Target Enriched in KMT2A-Rearranged Acute Myeloid Leukemia

Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute L

A Novel Antibody-Drug Conjugate Targeting the CD179a Component of the Surrogate Light Chain for the Treatment of B-Cell

AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Antibody Drug Conjugates with a Novel Translation Inhibitor Payload Demonstrate Cytotoxicity and Tumor Growth Reduction

Identifying and overcoming mechanisms of resistance to a VpreB1-directed antibody-drug conjugate in the treatment of B-c

Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mut

Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients

A novel and highly effective truncated BCMA safety switch for adoptive cell therapy

Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of supe

Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Application of Inotuzumab Ozogamicin in Children with B-ALL

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in pati

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cel

High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK

Myeloma: next generation immunotherapy.

Bispecifics, trispecifics, and other novel immune treatments in myeloma.

CD74 Is Expressed in Relapsed and Refractory Multiple Myeloma and Can be Targeted with a Novel Anti-CD74 Antibody Drug C

Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Effici

PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing

Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Trea

Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at

An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing T

MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions f

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment o

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spe

Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improve

A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resista

Novel Amanitin-Based Antibody–Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer.

Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjug

Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–

Site-specific Dolasynthen antibody-drug conjugates exhibit consistent pharmacokinetic profiles across a wide range of dr

TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor

Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced An

Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Lin

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment o

Design and evaluation of ZD06519, a novel camptothecin payload for antibody drug conjugates.

HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safet

Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in p

Abstract A107: Accelerating and Advancing Targeted Therapeutics: A One-Stop Service Platform for ADC and Next-Generation

Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd,

- **DOI:** 10.1158/1535-7163.targ-23-ia003 - **Authors:** Raffaele Colombo - **Year:** 2023 - **Journal:** Molecular Can

Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in pa

Abstract B121: CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer ther

Abstract A119: ALX2004, a novel topoisomerase I inhibitor antibody-drug conjugate for the treatment of EGFR-expressing s

Abstract A065: Differential sensitivity of normal and tumor organoids to targeted therapies

Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphom

Abstract A137: GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), fo

Abstract A125: Devleopment of TROP2-targeted cytotoxic peptides and drug conjugates for treatment of triple negative bre

Abstract A136: Comparison of the bystander effects and killing capabilities of the HER2-targeting antibody drug conjugat

Abstract B122: 2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-dr

Abstract B030: Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers

Abstract IA05: Computational pathology in ADC drug development

Abstract A124: CBB-120: A TROP2-targeted dual-payload ADC combining Top1i and ATRi mechanisms demonstrates superior effi

Abstract B060: Neratinib in combination with antibody–drug conjugates for patients with metastatic cancer

Abstract C004: ADC screening platform, a useful platform for ADC drug evaluation

Abstract 5819: An anti-TROP2-CPT113 ADC, exhibits potent targeted antitumor activity and favorable pharmacokinetic prope

Abstract 3147: DXC025, a novel anti-MUC1/EGFR bispecific antibody-tubulysin conjugate with a function linker, exhibits p

Abstract 5805: A novel platform of diversified payloads to drive ADC innovation

Abstract 7179: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties a

Abstract 5733: Development of a topoisomerase 1 inhibitor platform technology for efficacious and well tolerated ADCs

Abstract 5814: EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates

Abstract 731: pHLIP targeted intracellular delivery of calicheamicin

Abstract 4689: 4HF CancerDataMiner platform accelerates target discovery and evaluation

Abstract 6344: Engineering of ICAM-1 refractory antibodies for the development of therapeutic antibodies and antibody dr

Abstract 5083: Discovery of an asymmetric IgG-like bispecific ADC targeting EGFR/HER3

Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

Abstract 7215: Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry

Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-0

Abstract 6734: Preclinical impact of pretreatment with CRS mitigation agents on pharmacodynamic response to TAK-500, a s

- **DOI:** 10.1158/1538-7445.am2024-lb127 - **Authors:** Yifu Zhang, Chengzhang Shang, Chaoshe Guo, Yi Yang - **Year:**

Abstract 7183: Liver toxicity of amanitin-based antibody drug conjugates (ATACs) is caused by unspecific uptake of the A

Abstract LB058: N-glycan deglycosylation ameliorates anti-HER2 antibody drug conjugate-induced interstitial pneumonia in

Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody

Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with a

Abstract 1554: Harnessing the Beacon® optofluidic platform for streamlined discovery of internalizing antibodies

Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothel

Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7

Abstract LB025: CKD-703, a novel antibody-drug conjugate targeting cMET with an enhanced therapeutic index in solid tumo

Abstract 743: Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC dem

Abstract 1159: Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCR

Abstract CT179: Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose

Abstract 1230: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid

Abstract CT174: A phase 1 study of JBH492, an anti C-C chemokine receptor 7 antibody-drug conjugate (anti-CCR7 ADC), ass

Abstract 1567: GLR1059, next-generation nectin-4-targeted ADC with a novel mechanism-of-action payload, demonstrated sig

Abstract 1578: Preclinical evaluation of BLB-101, a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate f

Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment o

Abstract 1164: SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advan

Abstract 1716: Acquired cell adhesion molecule 1 (CADM1) ADC resistance model for optimizing payload efficacy and toxici

Abstract 1587: A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low i

Abstract 1799: Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile D

Abstract 1576: RenBiologics- a fully human antibody library generated by RenMice facilitates the development of antibody

Abstract 1761: SYNB011128: A novel bispecific peptide-drug-conjugate targeting EGFR and CAIX

Abstract 1579: PA289, a prodrug linker-payload with a novel mechanism of action for the development of antibody drug con

Abstract 1805: Dual-payload TME-activated ADC platform

Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pr

Abstract 1798: K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective t

Abstract 1804: An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently ov

Abstract 2693: BA3361, a tumor selective, conditionally active biologic (CAB) anti-nectin4-ADC with a novel NextGen link

Abstract 2120: A novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal canc

Abstract 1793: Pre-targeting with in vivo click chemistry enables preferential drug exposure in tumors versus normal tis

Abstract 1790: Enhancing ADC efficacy through Fc-binding peptide engineered with ECM binding moiety: A versatile platfor

- **DOI:** 10.1158/1538-7445.am2025-1786 - **Authors:** Ju-hyung Kang, Daekyun Lee, Seo-young Kwak, Jieon Lee - **Year:*

Abstract 1841: NanoGhost - A drug targeting system for treatment of solid tumors

- **DOI:** 10.1158/1538-7445.am2025-2875 - **Authors:** Elin Jaensson Gyllenback, C. Millrud, Olga Ab, D. Liberg - **Yea

Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and br

Abstract 2877: MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated poten

Abstract 2876: BR116: An antibody drug conjugate targeting CDH17 for gastrointestinal cancer therapy

Abstract 2870: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtu

Abstract 2872: DXC018: A novel HER2 dual-payload bispecific ADC with promising potential for gastrointestinal cancers an

Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of s

Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload

Abstract 2869: DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and sa

Abstract 2940: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment

Abstract 2934: Novel hydrophilic CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical xen

Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity

Abstract 3104: The mechanism of action of ADCs are dependent on Rab GTPases

Abstract 2878: Preclinical characterization of GLR1061, a B7H3-targeted ADC with a novel DNA topoisomerase I inhibitor,

Abstract 3307: Utilizing endocytosis as a predictive biomarker for ADCs

Abstract 2959: PF-08046031: A promising first-in-class antibody-drug conjugate for targeting novel tumor antigen in mela

- **DOI:** 10.1158/1538-7445.am2025-2884 - **Authors:** Mengyao Xu, Bo R. Rueda, David R. Spriggs, Yeku Oladapo - **Year

Abstract 2160: Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and -migration in viable hu

Abstract 2882: Development and preclinical characterization of HER2×Trop-2 bispecific antibody-drug conjugates (bsADCs)

Abstract 2966: The anti-tumor activity of a novel anti-Her2 and anti-c-Met bispecific antibody-drug conjugate

Abstract 3132: Innovative development of IMB-201, an anti-HLA-G antibody-drug conjugate (ADC), for enhanced tumor immuno

- **DOI:** 10.1158/1538-7445.am2025-337 - **Authors:** Floris van Delft, Lianne Lelieveldt, Jasper van de Sande, Anette

Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optim

Abstract 2965: SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate

Abstract 3122: A novel solid tumor-tissue-penetrating platform technology: Overcoming tumor microenvironment barriers fo

Abstract 311: Long-term tumor growth inhibition and extended survival with TD001, a novel optimized PSMA-targeting ADC,

Abstract 351: Preclinical development of MHB009C: A novel anti-B7-H4 ADC with a potent topoisomerase I inhibitor

Abstract 3140: Preclinical development of YL242, a non-internalized antibody-drug conjugate (ADC) targeting soluble VEGF

Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein wit

Abstract 315: Dose-response and tumor size at time of treatment with TD001, a novel ADC against PSMA, drive potent tumor

Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecul

Abstract 4356: OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokine

Abstract 4328: Preclinical development of SCR-A008: A CDH17-targeted ADC for gastrointestinal cancer

Abstract 4256: HY0001a: A novel antibody-drug conjugate (ADC) targeting CUB domain containing protein 1 (CDCP1)

Abstract 4780: Engineered ICAM-1 refractory trastuzumab improves its therapeutic activity against HER2-positive cancers

Abstract 353: Preclinical development of MHB048C: A novel anti-PSMA ADC with a potent topoisomerase I inhibitor

Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumo

Abstract 4270: Targeting CNTN4 with exatecan-based antibody-drug conjugate for the treatment of solid tumors

Abstract 5451: JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and H

Abstract 4255: Membrane interactomics (MInt) platform identifies EGFR and CDCP1 as effective co-targets for bispecific a

Abstract 5444: ImmuMab® mice enable efficient development of antibody therapeutics by unparalleled diversity across mult

- **DOI:** 10.1158/1538-7445.am2025-469 - **Authors:** Seung-hwan Jeong, Seokbong Hong, H. Yuk, Cheol Kwak - **Year:** 2

Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC

Abstract 4778: ADCE-T02: A first-in-class topoisomerase-1 inhibitor based antibody drug conjugate against tissue factor

Abstract 5447: Development and preclinical evaluation of JK06, a biparatopic ADC against 5T4

Abstract 4337: SYS6051, a next-generation tissue factor-targeted antibody-drug conjugates for the treatment of TF-expres

Abstract 4751: CS5005: A novel SSTR2-targeted antibody-drug conjugate (ADC) with robust antitumor activity in preclinica

Abstract 4783: Development and characterization of an antibody-drug conjugate (ADC) utilizing PB-223, a novel monoclonal

Abstract 5463: AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against ta

Abstract 5467: Therapeutic potential of antibody-drug conjugate with PARP1 selective inhibitor as a payload: A promising

Abstract 5469: Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting cadherin 17 (CDH17) for t

Abstract 5453: E-M ADC, a promising EGFR-MUC1 bispecific antibody drug conjugate, with superior anti-tumor effect in a w

Abstract 3836: Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and

- **DOI:** 10.1158/1538-7445.am2017-1820 - **Authors:** J. Teo, H. Tan, R. Huang, A. Choo - **Year:** 2017 - **Journal:*

Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lympho

Abstract 36: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificit

Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs

Abstract LB-222: Optimization and preclinical characterization of highly potent and stable anti-CD70 ADCs for the potent

Abstract 3111A: ADCT-401/MEDI3726, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting PSM

Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate t

Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2,

Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (A

Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometri

Abstract 751: A controlled affinity-guided ADC-linker (MAGNET) technology

Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolo

Abstract 3912: Towards development of next-generation biparatopic ADCs using a novel linker-toxin with expanded therapeu

- **DOI:** 10.1158/1538-7445.am2018-745 - **Authors:** Sreedhar Reddy Suthe, H. Yao, P. Trippier, Ming-Hai Wang - **Year

- **DOI:** 10.1158/1538-7445.am2018-2780 - **Authors:** L. Cheung, K. Mohamedali, W. Hittelman, M. Rosenblum - **Year:**

Abstract 3717: α3β1-Integrin targeted DM1 micellar prodrug for targeted therapy against ovarian cancer

Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit

Abstract 757: Novel warheads for targeted therapies of cancer: The concept and design of oxime-ether-based pro-PBDs

Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid c

Abstract 750: Modular coiled-coil masking domains for tumor-specific antibody activation

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

Abstract 2900: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates

Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug

Abstract 755: Synthesis and evaluation of sugar alcohol based molecules for drug conjugation and delivery

Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)

Abstract 231: Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dip

Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor acti

Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increa

Abstract 225: TR1801-ADC, an optimized anti cMet PBD ADC with high efficacy in solid tumors of the GI tract and head &am

Abstract CT053: BAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity f

Abstract 2901: Gastric cancer antibody fragment drug-conjugates (FDCs): From concept to clinical development

Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Abstract 4815: Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multi

Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 an

Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors

Abstract 2889: SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activi

Abstract 983: Antibody-drug conjugates of NAMPT inhibitors: Discovery, optimization, and preclinical characterization

Abstract 4054: Development of a new site-specific sulfomaleimide rebridging platform for the generation of homogeneous,

Abstract 4821: Development of a potent Trop-2 antibody-drug conjugate, BAT8003, for the treatment of Trop-2 positive gas

Abstract 921: Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synerg

Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cance

Abstract LB-227: Preclinical development and characterization of STI-6129, an anti-CD38 antibody-drug conjugate, as a ne

Abstract 3374: Development of novel and improved monoclonal antiMUC16 antibodies for the targeted therapy of ovarian can

Abstract 1405: Novel ADC platform delivers promising in vivo activity and safety

Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based

Abstract LB-063: Phospholipid drug conjugates show specificity for a broad range of tumor cells and provides a novel app

Abstract 909: Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors

Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models

Abstract 1873: GlycoConnect™ ADCs based on topoisomerase 1 inhibitor exatecan (SYNtecan E™) show excellent in vivo effic

Abstract 1760: The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positiv

Abstract 1763: Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail

Abstract 1764: Development of an alphalex™-auristatin low pH targeting conjugate for the treatment of solid tumors

Abstract 1753: IKS014, a HER2-targeting antibody drug conjugate incorporating novel bioconjugation and tumor-selective l

Abstract 1759: PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse

Abstract 1762: A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and

Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast

- **DOI:** 10.1158/1538-7445.am2022-2886 - **Authors:** Maria Klimovich, L. Zekri, G. Jung, H. Salih - **Year:** 2022 -

Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate

Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel top

Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid tumors that express TROP-2 using the hu2G10 tumor-sele

Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosph

Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by deliveri

Abstract 4256: YH012, a novel bispecific anti-HER2 and TROP2 antibody-drug conjugate, exhibits potent antitumor efficacy

- **DOI:** 10.1158/1538-7445.am2022-6227 - **Authors:** Jin-Ock Kim, Hanjun Ko, Jae-Won Kim, Sang Gyu Park - **Year:** 2

Abstract 326: Engineered toxin bodies (ETBs) targeting Trop2

Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and

Abstract 5566: Evaluation of the efficacy of ADC in vitro and in vivo

Abstract 6020: Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody dr

Abstract 452: Development and implementation of image analysis-based Quantitative Continuous Score (QCS) for B7-H4 IHC t

- **DOI:** 10.1158/1538-7445.am2023-1548 - **Authors:** G. Kaushik, Bandana A. Vishwakarma, Marina Bell, K. Komurov - **

Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- t

- **DOI:** 10.1158/1538-7445.am2022-5553 - **Authors:** Liang Du, T. Wan, Yi Jin, Ji-jun Yuan - **Year:** 2022 - **Journ

Abstract 6334: In vivo efficacy and toxicity of a reduced potency DNA guanine mono-alkylating ADC payload suitable for t

Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker st

Abstract LB021: TJ102: A promising bispecific dual-payload ADC targeting CDH6 and folate receptor alpha (FRα) for the tr

0595 TITLE : Prostate-Specific Membrane Antigen ( PSMA ) Targeted Bio-orthogonal Therapy for Metastatic Prostate Cancer

Efficient payload delivery by a bispecific antibody targeting HER2 and CD63

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved ADCs—A Necessity for Future ADC Re

Mechanisms contributing to ado-trastuzumab emtansine ( TDM 1 )-induced toxicities : a gateway to better understanding AD

INCORPORATING GLUTAMIC ACID-VALINE-CITRULLINE LINKER IN TRIFUNCTIONAL MOLECULES TARGETING PSMA ENSURES ENHANCED STABILIT

is not an appropriate payload of antibody-drug conjugates as rapid inactivation by lysosomal enzymes

BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity i

Scaling Amatoxin Synthesis with an Improved Route to (2S,3R,4R)-Dihydroxyisoleucine Exemplified by a Toxic, Clickable α-

Advances in antibody-drug conjugates for endometrial cancer.

Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-fola